Acute respiratory infections are a major cause of death in children under 5 years old globally. They can affect any part of the respiratory tract from the nose to the alveoli. The document discusses epidemiological factors like agents, host factors, and environmental factors that influence ARIs. It also provides classifications and treatment guidelines for ARIs in different age groups. Preventive measures discussed include addressing issues like malnutrition, indoor and outdoor air pollution, tobacco use, and overcrowding.
Acute respiratory infection in children, etiology, clinical features, diagnosis, treatment. Common infections in children including common cold, tonsillitis, LTB, Croup, Epiglottitis etc.
influeza and diptheria -Dr Krishna Smirthi CV.pptxKrishnaSmirthi
Acute infectious
disease caused by
toxigenic strains of
Corynebacterium
diphtheriae
3 major clinical
types anterior
nasal, faucial,
laryngeal
Skin,conjunctiva,
vulva and other
parts may be
affected
Fever, common cold and cough in pediatric age groups are common. Acute bronchiolitis is a diagnostic term used to describe the clinical picture produced by several different lower respiratory tract infections in infants and very young children (younger than 1yr ,some clinicians extend it to the age of 2 yr). Pneumonia defined as inflammation of lung parenchyma.
It is the leading infectious cause of death globally among children younger than 5 yr.
The introduction of antibiotics and vaccine against measles , pertussis ,haemophilus influenzae type b and PCV vaccine reduces the pneumonia related mortality over past 15 yr.
Acute respiratory infection in children, etiology, clinical features, diagnosis, treatment. Common infections in children including common cold, tonsillitis, LTB, Croup, Epiglottitis etc.
influeza and diptheria -Dr Krishna Smirthi CV.pptxKrishnaSmirthi
Acute infectious
disease caused by
toxigenic strains of
Corynebacterium
diphtheriae
3 major clinical
types anterior
nasal, faucial,
laryngeal
Skin,conjunctiva,
vulva and other
parts may be
affected
Fever, common cold and cough in pediatric age groups are common. Acute bronchiolitis is a diagnostic term used to describe the clinical picture produced by several different lower respiratory tract infections in infants and very young children (younger than 1yr ,some clinicians extend it to the age of 2 yr). Pneumonia defined as inflammation of lung parenchyma.
It is the leading infectious cause of death globally among children younger than 5 yr.
The introduction of antibiotics and vaccine against measles , pertussis ,haemophilus influenzae type b and PCV vaccine reduces the pneumonia related mortality over past 15 yr.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
2. INTRODUCTION
ARI responsible for 20% of childhood(<5yrs) death
90% from pneumonia
ARI mortality highest in children
HIV infected
Under 2yr of age
Malnourished
Weaned early
Poorly educated parents
Difficult assess to health
Out patient visits
30-50%
Admissions
20-40%
ARI & TB influenced by HIV
3. CONT.
ARI can affect anywhere from nose to alveoli.
ARIs can be classified into –
Acute upper respiratory tract infections (common
cold,pharyngitis& otitis media).
Acute lower respiratory tract
infections(Epiglottitis,Laryngitis,Laryngotracheitis,Br
onchitis,Bronchiolitis,Pneumoniae).
In less developed countries measles and whooping
cough are major cause of respiratory tract infections.
7. HOST FACTORS
AGE- Small children are most vulnerable.
-upper respiratory tract infection is more
common in chidren than adults.
-Illness rate more common in younger children
and decreases with increasing age.
Under FIVE years children
SEX –Equal ,but reporting MALE >FEMALE
In adults , FEMALE > MALE
(Due to more association with children)
8. IMMUNE STATUS – Nutritional status :
1. Healthy
2. malnourished
3. low birth weight
HISTORY OF VACCINATION:
1. DPT
2. PNEUMOCOCCAL VACCINE
3. BCG
4. MEASLES,etc.
SOCIOECONOMIC STATUS:- In low socioeconomic
status more chances of acute respiratory infection.
9. ENVIRONMENTAL FACTORS
SOCIAL :-
Overcrowding
poor housing
low standard of living
poor knowledge/awareness/ignorance
Indoor smoke pollution
Maternal smoking
Level of industrialization
BIOLOGICAL :-
Bacterial
Viruses , etc.
SEASONAL:- In winter season , more ACUTE RESPIRATORY
INFECTION
11. TOP TEN CAUSES OF DEATH:WORLDWIDE TOP TEN CAUSES OF DEATH:DEVELOPING WORLD
1 Ischemic heart disease 12.2%
2 Cerebrovascular
disease
9.7%
3 Lower respiratory
infection(accounts for
most ARIs)
7.1%
4 Chronic obstructive
pulmonary disease
5.1%
5 Diarrheal diseases 3.7%
6 HIV/AIDS 3.5%
7 Tuberculosis 2.5%
8 Trachea,bronchus,lun
g cancers
2.3%
9 Road traffic accidents 2.2%
10 Prematurity & low
birthweight
2.0%
1 Lower respiratory
infection(accounts
for more ARIs)
11.2%
2 Ischemic heart
disease
9.4%
3 Diarrheal diseases 6.9%
4 HIV/AIDS 5.7%
5 Cerebrovascular
disease
5.6%
6 Chronic obstructive
pulmonary disease
3.6%
7 Tuberculosis 3.5%
8 Neonatal infections 3.4%
9 Malaria 3.3%
10 Prematurity & low
birthweight
3.2%
12. Etiology in special groups
Group Organisms Antibiotic
Immune
compromised
Gram negative
S. aureus
Opportunistic
Pneumocystis jiroveci
M. tuberculosis
Ampicillin +
Cloxacillin +
Aminoglycoside
Less than 3
months
Gram negative
Group B streptococcus
S.aureus
Ampicillin +
Aminoglycoside
Hospital
acquired
pneumonia
Gram negative
Methicillin resistant S.
aureus
Aminoglycoside +
Vancomycin +
Cephalosporin (3rd
generation)
13. CLASSIFICATION OF ILLNESS
(child aged 2 months to 5 yrs)
Classifying the illness means making decisions about
the type and severity of the disease . The sick child
should be put in to one of the four classification:
VERY SEVERE DISEASE
SEVERE PNEUMONIA
PNEUMONIA(NOT SEVERE)
NO PNEUMONIA
15. CLASSIFICATION AND MANAGEMENT
( AGE BETWEEN 2 MONTHS UPTO 5 YEARS)
CLASSIFY AS CLINICAL SIGNS TREATMENT
NO
PNEUMONIA
COUGH,
NO T ACHYPNOEA
SUPPORTIVE MEASURES,
ANTIPYRETIC,
NO ANTIBIOTICS
PNEUMONIA COUGH,
TACHYPNOEA,
NO RIB OR STERNAL
RETRACTION
SUPPORTIVE MEASURES,
ANTIPYRETIC,
ANTIBIOTICS
SEVERE
PNEUMONIA
COUGH,
T ACHYPNOEA,
RIB OR STERNAL RETRACTION
SUPPORTIVE MEASURES,
ANTIBIOTICS,
REFER TO HOSPITAL
VERY SEVERE
DISEASE
COUGH,
TACHYPNOEA,
CHESTWALL RETRACTION,
UNABLE TO DRINK,
CYANOSIS,
CONVULSIONS,
ABNORMALLY SLEEPY OR DIFFICULT
REFER URGENTLY TO HOSPITAL,
GIVE 1st DOSE OF AN
ANTIBIOTIC,ANTIPYRETIC IF FEVER
PRESENT,TREAT WHEEZING IF
PRESENT
16. CLASSIFICATION&MANAGEMENT OF ILLNESS IN YOUNG INFANTS (
LESS THAN 2 MONTHS)
CLASSIFY AS SIGNS TREATMENT
NO
PNEUMONIA:
COUGH OR
COLD
NO SEVERE CHEST
INDRAWING & NO FAST
BREATHING ( RR < 60/MIN.)
ADVICE MOTHER TO GIVE THE FOLLOWING HOME
CARE :
•KEEP YOUNG INFANT WARM
•BREAST FEED FREQUENTLY
•CLEAR NOSE IF IT INTERFERES WITH FEEDING.
•RETURN QUICKLY IF
:-
•BREATHING BECOME DIFFICULT
•BREATHING BECOMES FAST
•FEEDING BECOMES A PROBLEM ,THE INFANT
BECOMES SICKER.
SEVERE
PNEUMONIA
SEVERE CHEST
INDRAWING,OR FAST
BREATHING(60 Per min or
more)
REFER URGENTLY TO HOSPITAL.
KEEP YOUNG INFANT WARM.
GIVE FIRST DOSE OF AN ANTIBIOTIC.
VERY SEVERE
DISEASE
STOPPED FEDING WELL,
CONVULSIONS,
ABNORMALLY SLEEPY OR
DIFFICULT TO WAKE,
STRIDOR IN CALM CHILD,
WHEEZING,OR FEVER or LOW
REFER URGENTLY TO HOSPITAL,
KEEP YOUNG INFANT WARM,
GIVE FIRST DOSE OF AN ANTIBIOTIC.
17. TREATMENT OF PNEUMONIA IN CHILDREN
(AGED LESS THAN 2MONTHS )
ANTIBIOTIC DOSE FREQUENCY
Age<7days Age7 days to
2month
Inj . Benzyl
penicillin OR
50,000IU/kg/dose 12hourly 6hourly
Inj. Ampicillin
AND
50mg/kg/dose 12hourly 8hourly
Inj . Gentamycin 2.5mg/kg/dose 12hourly 8hourly
18. DANGER SIGNS
HIGH RISK OF DEATH FROM
RESPIRATORY
ILLNESS:-
- Younger than two months
- Decreased level of consciousness
- Stridor when calm
- Severe malnutrition
- Associated symptomatic HIV/AIDS
19. TACHYPNOEA
Less than 3 month >60 breaths per minute
3 months to 12 months >50 breaths per minute
1 year to 4 years > 40 breaths per minute
20. MEASURES BEFORE
TRANSFERRING TO HOSPITAL
Antipyretics
Oxygen
-40% by mask or prongs
Suctioning of secretions
Stomach tube
- For decompression
-Give fluids
Severely distressed,IV fluids
Intravenous penicillin
21. Clinical picture
Neonates may have non-specific signs
– Lethargy, failure to feed, temperature instability,
apnoea or tachypnoea
Older children
– Runny nose , sore throat followed by cough, fever and
tachypnoea
More serious pneumonia
– Tachypnoea, chest indrawing, feeding difficulty
Respiratory failure
– Severe tachypnoea, chest indrawing, restlessness,
grunting, tachycardia and central cyanosis
22. EXAMINATION
o Altered breath sounds and crackles
o Signs of lobar pneumonia in minority
- dullness to percussion , bronchial breathing
o Mild pneumonia only tachypnoea
o Measure severity of hypoxia with transcutaneous
saturation monitor
o Sudden deterioration suggestive of complication
-Pneumothorax , pyopneumothorax
25. TREATMENTS WITH NO PROVEN
BENEFIT IN ACUTE PNEUMONIA
IN CHILDREN
Mucolytics
Chest physiotherapy
Postural drainage
Nebulization
26. FAILURE TO RESPOND
Incorrect or inadequate dose of antibiotic
Resistant or not suspected organism
Empyema or other complications
TB
Suppressed immunity
Underlying cause
E.g.Foreign body or bronchiectasis
Left heart failure and not pneumonia
Refer if no improvement after 3-5 days
27. PROGNOSIS
Most children recover without residual
damage
Incorrect treatment leads to tissue
destruction and bronchiectasis
Half of children with pneumonia
secondary to measles or adenovirus
have persistent airway obstruction
28. PREVENTIVE MEASURES
Taking action against poverty, improving standards of
living & addressing the envoirnmental factor that create
the conditions for the spread of disease can dramatically
reduce ARIs. Other , more targeted streategies are:
MALNUTRITION:-
• Exclusive breastfeeding before six month
• Breastfeeding & complementary foods until age two.
• Access to appropriate nutritional supplements.
• Commitment from governments & the international
community to combat malnutrition.
29.
30. AIR POLLUTION:-
o Wider access to cleaner fuels for cooking & heating .
o Support & education to help people change their cooking
habits.
o More research into the relationship between indoor air
pollution & health.
o Motor vehicle & industrial emission controls .
o Improved public transportation system to reduce to motor
vehicle use.
CLEANER COOKING FUELS ,REDUCED TOBACCO USE, &
VEHICLE EMISSION CONTROLS REDUCE POLLUTION & ARIs.
32. TOBACCO
Raise tobacco prices.
• Enforce no-smoking policies .
• Provide education about the harms of smoking &
second hand smoke.
• Ban all forms of tobacco advertising & marketing.
• Expand the use of health warnings on cigarettes .
SMOKERS ARE SIGNIFICANTLY MORE LIKELY TO DEVELOP A
VARIETY OF RESPIRATORY ILLNESSES ,INCLUDING PNEUMONIA
,INFLUENZA & TUBERCULOSIS & THEIR CASES ARE MORE LIKELY
TO BE SEVERE.
34. OVERCROWDING
ARIs are less likely to spread in communities with well
–ventilated houseing that meets density standards .
GLOBAL IMPACT
By 2015 ,more than 75% of the worlds slum dwellers will live in sub –
Saharan Africa & parts of Asia ,in conditions that promote the
spread of ARIs.
By 2050 ,almost 70% of the worlds Popullation will live in cities .
Alleviating overcrowding is closely tied to broader efforts to address
poverty ,manage growth improve urban infrastructure ,& foster
economic development .